Related Experiment Videos
The outlook for alemtuzumab in multiple sclerosis
Thomas Williams1, Alasdair Coles, Laura Azzopardi
1Department of Clinical Neurosciences, Addenbrooke's Hospital, University of Cambridge, Box 165, Cambridge, CB2 0QQ, UK.
Summary
Alemtuzumab, an anti-CD52 antibody, resets the immune system for multiple sclerosis (MS) treatment. Clinical trials show sustained reduction in relapses and disability over 5 years.
Area of Science:
- Immunology
- Neurology
- Pharmacology
Background:
- Alemtuzumab is a humanized anti-CD52 monoclonal antibody.
- Its administration induces profound lymphopenia, leading to immune system 'reset' via homeostatic lymphocyte reconstitution.
- Relapsing-remitting multiple sclerosis (RRMS) is a chronic autoimmune disease affecting the central nervous system.
Purpose of the Study:
- To evaluate the efficacy and safety of alemtuzumab in patients with relapsing-remitting multiple sclerosis.
- To compare alemtuzumab with interferon-beta, a current first-line therapy for RRMS.
- To discuss the future outlook of alemtuzumab in the context of existing multiple sclerosis treatments.
Main Methods:
- One Phase II and two Phase III randomized, multicenter, single-blinded clinical trials.
- Comparison of alemtuzumab against an active comparator (interferon-beta).
- Assessment of annualized relapse rate, disability accumulation, and adverse events.
Main Results:
- Alemtuzumab significantly reduced the annualized relapse rate in RRMS patients.
- Significant reduction in disability accumulation was observed with alemtuzumab treatment.
- Treatment effects were sustained for at least 5 years post-therapy.
- Common adverse effects included infusion reactions, infections, and secondary autoimmunity (e.g., thyroid disease).
Conclusions:
- Alemtuzumab demonstrates sustained efficacy in reducing relapses and disability in RRMS.
- The immune system reset mechanism offers a novel therapeutic approach for MS.
- Safety profile includes manageable side effects, with secondary autoimmunity requiring monitoring.
Related Concept Videos
01:19Multiple Sclerosis l: Introduction
Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
01:20Myasthenia Gravis: Overview and Treatment
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...